FDA Advisers Back Novavax Vaccine for Authorization

Vaccine experts advising the FDA have endorsed a new Covid vaccine made by Novavax saying that the shot’s benefits outweigh any risks associated with it.  The vaccine will still need full approval before coming on the market, but it will be the first one available using a more traditional, protein-based technology.  Liz Essley Whyte, reporter at the WSJ, joins us for what to know about its effectiveness and concerns. See omnystudio.com/listener for privacy information.